Clinical Trial Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, variants, or PubMed publications.

Have questions, comments or suggestions? - Let us know!

Email us at : ckbsupport@jax.org

NCT ID NCT03580694
Title Study of REGN4659 in Combination With Cemiplimab in Patients With Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC)
Recruitment Terminated
Gender both
Phase Phase I
Variant Requirements Yes
Sponsors Regeneron Pharmaceuticals
Indications

lung non-small cell carcinoma

Therapies

Cemiplimab + REGN4659

Cemiplimab

Age Groups: senior | adult
Covered Countries USA

Facility Status City State Zip Country Details
Regeneron Investigational Site Chicago Illinois 60637 United States Details
Regeneron Investigational Site Grand Rapids Michigan 49546 United States Details
Regeneron Investigational Site Charlotte North Carolina 28204 United States Details
Regeneron Investigational Site Oklahoma City Oklahoma 73104 United States Details
Regeneron Investigational Site Nashville Tennessee 37203 United States Details
Regeneron Investigational Site San Antonio Texas 78229 United States Details
*Shaded cells indicate that there was no data available from clincialtrials.gov for the field